A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects
Immune checkpoint inhibitors, such as ipilimumab and nivolumab, reverse the imbalance of antitumor self-tolerance and enhance T-cell responses. Currently, ipilimumab and nivolumab have a reported therapeutic impact on unresectable or metastatic melanomas; however, they also induce immune-related adv...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2018-01-01
|
Series: | Case Reports in Dermatology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/485910 |